Xencor (XNCR) Other financing activities (2014 - 2026)
Xencor (XNCR) posted quarterly Other financing activities of $950000.0 for Q1 2026, down 68.06% year-over-year from $3.0 million in Q1 2025, and down 88.13% quarter-over-quarter from $8.0 million in Q4 2025.
Powered by 
Analysis
Xencor (XNCR) Other financing activities (2014 - 2026) Analysis & Trends
Xencor (XNCR) has reported Other financing activities for 13 consecutive years, with $950000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 68.06% year-over-year to $950000.0; the TTM figure through Mar 2026 stood at $6.6 million (up 459.65% YoY), while the FY2025 annual figure was $8.7 million, changed N/A from the prior year.
- Other financing activities fell to $950000.0 in Q1 2026 per XNCR's latest filing, from $8.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $8.0 million in Q4 2025 and bottomed at -$2.3 million in Q3 2025.
- Historically, Other financing activities has averaged $1.1 million across 5 years, with a median of $922000.0 in 2023.
- Annual changes were most pronounced in 2024 — Other financing activities tumbled 367.81% — and 2025, when it jumped 960.75%.
- Xencor's Other financing activities stood at $276000.0 in 2022, then jumped by 427.17% to $1.5 million in 2023, then sank by 163.92% to -$930000.0 in 2024, then surged by 960.75% to $8.0 million in 2025, then sank by 88.13% to $950000.0 in 2026.
- Business Quant data shows XNCR's Other financing activities at $950000.0 in Q1 2026, $8.0 million in Q4 2025, and -$2.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 46,000.00 |
| Mar 31, 2026 | 950,000.00 |
| Dec 31, 2025 | 5.69 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | 3.70 Mn |
| Sep 30, 2024 | 685,000.00 |
| Jun 30, 2024 | 140,000.00 |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 1.46 Mn |
| Sep 30, 2023 | 356,000.00 |
| Jun 30, 2023 | 679,000.00 |
| Mar 31, 2023 | 922,000.00 |
| Dec 31, 2022 | 276,000.00 |
| Sep 30, 2022 | 1.29 Mn |
| Jun 30, 2022 | 1.32 Mn |
| Mar 31, 2022 | 731,000.00 |
| Dec 31, 2021 | 2.81 Mn |
| Sep 30, 2021 | 3.23 Mn |
| Jun 30, 2021 | 903,000.00 |
| Mar 31, 2021 | 5.34 Mn |